Insufficient evidence
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No clinical study evaluated the effect of renal impairment on deutetrabenazine or its main metabolites. Limits and monitoring The cited pharmacokinetic gap supplies no renal dose or dialysis timing rule. Confirm immediate- or extended-release instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 36, posted Oct 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment is expected to have little influence on systemic exposure to the active proton pump inhibitor. Limits and monitoring This pharmacokinetic prediction supplies no dialysis timing or supplemental dose. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 40, posted Feb 24, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The label's comparison found no significant differences in dexmedetomidine pharmacokinetic measures at CrCl below 30 mL/min compared with normal renal function. Limits and monitoring A pharmacokinetic comparison does not establish a dialysis regimen. Verify the film formulation and monitoring. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Nov 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild and moderate renal impairment do not require dose reduction of dextromethorphan/quinidine. Limits and monitoring Verify the severe-impairment evidence separately. Consider the combination's QT and interaction risks. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 4, posted Jan 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Advanced renal disease is a reason to avoid diclofenac potassium powder for oral solution. Limits and monitoring If treatment is necessary, monitor renal function. Verify the formulation used for migraine. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Dec 16, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Avoid the controlled-release Norpace CR formulation at CrCl 40 mL/min or less. Immediate-release disopyramide has separate clearance-based intervals. Limits and monitoring Confirm the release formulation before selecting an interval and monitor conduction and anticholinergic toxicity. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 22, posted Aug 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment decreases valproate protein binding, which can change the relationship between total concentration and pharmacologically active free drug. Limits and monitoring Interpret total levels alongside clinical response and toxicity. Verify the delayed-release formulation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 1621, posted Apr 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Cockcroft-Gault CrCl with actual body weight, mL/min Renal action or finding Initial oral doses by calculated CrCl are 500 mcg twice daily above 60, 250 mcg twice daily at 40-60, and 125 mcg twice daily at 20 to below 40 mL/min. Below 20, use is contraindicated. Limits and monitoring Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 30, posted Apr 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment was not specifically studied. The label anticipates little change in doxepin exposure because little parent drug or active metabolite is excreted in urine. Limits and monitoring This observation concerns the low-dose insomnia tablet. It supplies no dialysis replacement schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Apr 24, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The drospirenone/ethinyl estradiol combination is contraindicated in renal impairment. Limits and monitoring Assess renal function and drugs that can increase potassium before prescribing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Jul 06, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The labeled dulaglutide regimen can be used across renal impairment categories, including ESRD. Limits and monitoring Use caution in ESRD and monitor renal function during adverse reactions that can cause volume depletion. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 62, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Mild or moderate renal impairment had no clinically important influence on durvalumab disposition in the cited analysis. Limits and monitoring Assess new kidney injury during immunotherapy separately from baseline pharmacokinetics. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 34, posted Sep 07, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
